EP
ZBIO

Essential Partners’s Zenas BioPharma ZBIO Stock Holding History

Essential Partners’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51 Hold
2
– – ﹤0.01% 2791
2026
Q1 		$39 Sell
2
-1
-33% -$22 ﹤0.01% 2797
2025
Q4 		$109 Buy
3
+1
+50% +$33 ﹤0.01% 2539
2025
Q3 		$44 Hold
2
– – ﹤0.01% 2581
2025
Q2 		$19 Buy
+2
New +$19 ﹤0.01% 2227

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Essential Partners's ZBIO Position: Q2 2026 in Review

Essential Partners held its Zenas BioPharma (ZBIO) position steady in Q2 2026 at 2 shares worth $51. The position accounts for ﹤0.01% of the portfolio, ranked #2791.

Essential Partners first reported a position in ZBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $109 in Q4 2025. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Essential Partners held 2 shares of Zenas BioPharma worth $51 as of Q2 2026.
  • Essential Partners left its Zenas BioPharma share count unchanged in Q2 2026.
  • Zenas BioPharma made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2791 holding.
  • Essential Partners first reported a position in Zenas BioPharma in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Zenas BioPharma position peaked at $109 in Q4 2025.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.